MP18-06 VALUE OF CIRCULATING MICRORNAS AS PROGNOSTIC BIOMARKERS IN UPPER TRACT UROTHELIAL CARCINOMA

Abstract

You have accessJournal of UrologyBladder Cancer: Upper Tract Transitional Cell Carcinoma I1 Apr 2018MP18-06 VALUE OF CIRCULATING MICRORNAS AS PROGNOSTIC BIOMARKERS IN UPPER TRACT UROTHELIAL CARCINOMA Ruth Montalbo, Laura Izquierdo, Mercedes Ingelmo-Torres, Juan Jose Lozano, Noelia Ventura, Antonio Alcaraz, and Lourdes Mengual Ruth MontalboRuth Montalbo More articles by this author , Laura IzquierdoLaura Izquierdo More articles by this author , Mercedes Ingelmo-TorresMercedes Ingelmo-Torres More articles by this author , Juan Jose LozanoJuan Jose Lozano More articles by this author , Noelia VenturaNoelia Ventura More articles by this author , Antonio AlcarazAntonio Alcaraz More articles by this author , and Lourdes MengualLourdes Mengual More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.582AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Upper tract urothelial carcinoma (UTUC) represents an aggressive disease with high recurrence and progression rates. The 5-year specific survival for these tumors is < 50% and 60% of them are invasive at the moment of diagnosis. Several studies have investigated the prognostic impact of various tissue-based markers that are related to different cellular processes. However, none of them has fulfilled the clinical and statistical criteria necessary to support their introduction in daily clinical decision making. In this study we aim to identify microRNA expression profiles in serum as a non-invasive prognostic tool for UTUC patients. METHODS Prospective study of serum samples from 33 UTUC patients (13 progressing and 20 non-progressing), who underwent radical nephroureterectomy in Hospital Clinic of Barcelona, Spain. Total RNA was isolated and expression of 800 microRNAs was analyzed using nCounter® miRNA Expression Assays (NanoString Technologies). Expression values of the 800 microRNAs were evaluated. The study was divided into an initial screening phase (n=12) and a validation phase (n=21). RESULTS Median age (range) of the cohort is 70 years (50-90). The median follow-up (range) was 42 months (9-100 months). Initial screening expression analysis identified 38 microRNA differentially expressed between the progressing and non-progressing UTUC patients (p<0.05). Of these, 9 were up-regulated and 29 were down-regulated. The validation phase, in an independent set of UTUC patients, demonstrated 18 microRNAs remaining differentially expressed between the two groups (8 progressing and 13 non-progressing). All validated microRNAs were down-regulated in progressing patients’ expression profiles. Survival models were used in this set of validated microRNAs. Cox Regression analysis showed miR-151b and stage as significant prognostic factors for tumor progression (p=0.000 and p=0.006 respectively) and cancer specific survival (p=0.000 and p=0.003 respectively). Finally, survival curves revealed that miR-151b is a statistically significant prognostic factor and discriminates between two groups of UTUC patients for progression prognosis (p=0.006) and for cancer specific survival (p=0.034). CONCLUSIONS Serum UTUC miRNA profiles can discriminate progressing versus non-progressing tumors. Further validation of these microRNAs in a larger cohort of patients is needed. This is the first study analyzing serum samples from UTUC patients. Detection of microRNAs in biofluids as serum could be a promising non-invasive tool to monitor progression in UTUC. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e215 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Ruth Montalbo More articles by this author Laura Izquierdo More articles by this author Mercedes Ingelmo-Torres More articles by this author Juan Jose Lozano More articles by this author Noelia Ventura More articles by this author Antonio Alcaraz More articles by this author Lourdes Mengual More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...